19 October 2026

strategyland.uk

Hikma Pharmaceuticals PLC (HIK)

Rank #73 of 280 - Healthcare - UK Equities

Home/Stocks/Healthcare

Hikma Pharmaceuticals PLC

HIK.L·Healthcare·Market Cap £3.4b

Rank #73 of 280

Quantitative Model · 280 Stocks Analysed

£16.12

+4.00% YTD

52W: £11.87 - £18.65

Factor Analysis Summary

Editorial assessment generated from Hikma Pharmaceuticals PLC's live factor scores and sector positioning.

Based on Strategyland's proprietary 7-factor analysis, Hikma Pharmaceuticals PLC (HIK.L) currently holds an overall rank of #73 out of 280 FTSE 100 constituents, reflecting its weighted composite score across liquidity, valuation, profitability, solvency, asset efficiency, market trading, and technical dimensions.

Key strengths include liquidity, where it demonstrates exceptional market liquidity with deep trading volumes that support efficient entry and exit, and technical (RSI 50.2), where it demonstrates generally favourable technical indicators with price holding above key moving averages.

Areas requiring attention include profitability (ROE 16.4%, net margin 11.5%), where compressed margins and weak returns on equity weigh on the earnings profile, as well as market trading, where low relative volume or adverse volatility patterns may deter momentum-oriented investors.

Within the Healthcare sector, Hikma Pharmaceuticals PLC sits at composite rank #73, outperforming the Healthcare peer average (rank 86). Among 7 Healthcare names in our coverage, it ranks above 4 peers and below 2.

At composite rank #73 (top 74% of the FTSE 100 universe), Hikma Pharmaceuticals PLC presents a mixed profile: liquidity provides the clearest positive signal, while profitability remains the primary constraint on its overall score.

Strongest Factors

Liquidity — Rank 52/280 (top quartile)
Technical — Rank 107/280 (above average)
Asset Efficiency — Rank 122/280 (middle of the pack)

Weakest Factors

Profitability — Rank 186/280 (below average)
Market Trading — Rank 180/280 (below average)

Score Analysis

Hikma Pharmaceuticals PLC is ranked #73 out of 280 UK stocks. Lower factor scores indicate better performance in that category.

Factor Breakdown

131/280

Average Score

Liquidity

Excellent52/280

Valuation

Fair127/280

Profitability

Weak186/280

Solvency

Fair144/280

Asset Efficiency

Fair122/280

Mkt Trading

Weak180/280

Technical

Good107/280

1. Liquidity

Score: 52/280

How liquid is HIK and can it meet its short-term obligations?

2/6

liquidity criteria met

Metric

Sector Range

Value

Rank

✓

Quick Ratio

1.0 - 2.5

1.06xRank 57/280

Range: 1.0 - 2.5Rank 57/280

✓

Current Ratio

1.5 - 2.5

1.82xRank 88/280

Range: 1.5 - 2.5Rank 88/280

✗

TTM Operating Cash Flow

0.8 - 1.5

0.23xRank 179/280

Range: 0.8 - 1.5Rank 179/280

–

Liquidity Coverage Ratio

N/A

Range: N/A

✗

Intangible Asset Ratio

5 - 20

0.14xRank 36/280

Range: 5 - 20Rank 36/280

✗

Cash-to-Debt Ratio

0.4 - 1.2

0.11xRank 195/280

Range: 0.4 - 1.2Rank 195/280

Key Liquidity Metrics

Quick Ratio

1.06x

Sector: 1.0 - 2.5

Current Ratio

1.82x

Sector: 1.5 - 2.5

Overall Liquidity Rank

Rank within universe#52/280

Best (1)Worst (280)

2. Valuation

Score: 127/280

Is HIK undervalued compared to its peers and fair value metrics?

2/7

valuation criteria met

Metric

Sector Range

Value

Rank

✗

FY27e P/E

15x - 30x

8.6xRank 38/280

Range: 15x - 30xRank 38/280

✗

FY26e P/E

15x - 30x

9.3xRank 36/280

Range: 15x - 30xRank 36/280

✗

FY27e Net Div Yld (%)

1.5 - 4.5

5.64%Rank 53/280

Range: 1.5 - 4.5Rank 53/280

✓

Div Payout Ratio

30 - 60

47.54%Rank 100/280

Range: 30 - 60Rank 100/280

✗

Current EV/EBITDA

9.0x - 16.0x

7.0xRank 106/280

Range: 9.0x - 16.0xRank 106/280

✓

Current P/TBV

2.0x - 7.0x

3.26xRank 156/280

Range: 2.0x - 7.0xRank 156/280

✗

Current P/B

2.0x - 6.0x

1.79xRank 155/280

Range: 2.0x - 6.0xRank 155/280

Key Valuation Metrics

TTM P/E

Price-to-Earnings

12.1x

FY26e P/E

Forward estimate

9.3x

FY27e P/E

Forward estimate

8.6x

Current P/B

Price-to-Book

1.79x

Current P/TBV

Tangible Book Value

3.26x

Current EV/EBITDA

Enterprise Value

7.0x

FY26e EV/EBITDA

Forward estimate

6.8x

FY27e EV/EBITDA

Forward estimate

7.1x

Dividend

HIK pays a dividend yield of 4.13%.

Current Yield

4.13%

FY27e Net Div Yield

5.64%

FY26e Gross DPS

0.858

FY27e Gross DPS

0.909

Dividend Per Share Forecast

3. Profitability

Score: 186/280

How profitable is HIK relative to its peers?

3/7

profitability criteria met

Metric

Sector Range

Value

Rank

✓

TTM Profit Margin

6 - 15

11.5%Rank 147/280

Range: 6 - 15Rank 147/280

✗

T12 FCF Margin

12 - 20

0.5%Rank 101/280

Range: 12 - 20Rank 101/280

✓

FY27e RoE

12 - 25

17.5%Rank 92/280

Range: 12 - 25Rank 92/280

✗

FY26 EPS Growth

8 - 15

1.3%Rank 164/280

Range: 8 - 15Rank 164/280

✓

FY27e EPS Growth

8 - 15

9.8%Rank 157/280

Range: 8 - 15Rank 157/280

–

NIM

N/A

Range: N/A

–

Expense Ratio

75 - 87

N/A

Range: 75 - 87

TTM Profit Margin

11.5%

Current RoCE

16.4%

FY27e RoE

17.5%

T12 FCF Margin

0.5%

EPS Growth

4. Solvency

Score: 144/280

How strong is HIK's balance sheet and financial position?

1/6

solvency criteria met

Metric

Sector Range

Value

Rank

✓

Debt/Eqt

0.2x - 0.7x

0.62xRank 160/280

Range: 0.2x - 0.7xRank 160/280

–

Interest Coverage Ratio

5x - 15x

Rank 153Rank 153/280

Range: 5x - 15xRank 153/280

✗

Net Leverage Ratio

0.5x - 1.5x

1.73xRank 110/280

Range: 0.5x - 1.5xRank 110/280

–

Altman Z-Score (Manufacturing)

<1.10 - >2.60

5.25Rank 120/280

Range: <1.10 - >2.60Rank 120/280

–

Z-Score (Non Manufacturing)

<1.10 - >2.60

Rank 145Rank 145/280

Range: <1.10 - >2.60Rank 145/280

–

CapAdeq Ratio Tier1

N/A

Range: N/A

Key Solvency Metrics

Debt/Eqt

0.62x

Net Leverage Ratio

1.73x

Interest Coverage

Rank 153

T12 FCF Margin

0.5%

Altman Z-Score

5.25

Safe Zone

01.812.995+

5. Asset Efficiency

Score: 122/280

How efficiently does HIK deploy its assets and intellectual capital?

1/5

asset efficiency criteria met

Metric

Sector Range

Value

Rank

–

Efficiency Ratio

N/A

Range: N/A

✗

TTM Asset Turnover Ratio

0.3x - 0.6x

0.60xRank 106/280

Range: 0.3x - 0.6xRank 106/280

✓

TTM CAPEX/Sales

6 - 10

8.7%Rank 56/280

Range: 6 - 10Rank 56/280

✗

Working Capital Turnover

4x - 7x

3.68xRank 100/280

Range: 4x - 7xRank 100/280

✗

R&D/Sales FY27e

12 - 25

6.3%Rank 15/280

Range: 12 - 25Rank 15/280

Overall Asset Efficiency Rank

Rank within sector peers#122/280

Best (1)Worst (280)

6. Market Trading

Score: 180/280

How liquid and actively traded is HIK?

1/2

market trading criteria met

Metric

Sector Range

Value

Rank

✗

Intraday Sentiment (%)

30 - 60

61.0%Rank 95/280

Range: 30 - 60Rank 95/280

–

10D-Avg v/s 3M-Avg Vol

N/A

57%Rank 100/280

Range: N/ARank 100/280

✓

Avg Directional Index 30D

010 - 40

20.4Rank 131/280

Range: 010 - 40Rank 131/280

–

Parabolic SAR

N/A

1565.46Rank 68/280

Range: N/ARank 68/280

–

Stock Rating Rank

N/A

Rank 100Rank 100/280

Range: N/ARank 100/280

Market Cap

£3,363,231,837

Enterprise Value

£6,135,251,648

Trading Volume

7. Technical

Score: 107/280

What do the technical indicators say about HIK?

0/5

technical criteria met

Metric

Chart

Sector Range

Value

Rank

–

CMP v/s 52-WH

£18.65£11.87

-13.6%CMP: £16.12

N/A

-13.6%Rank 157/280

£18.65£11.87

-13.6%CMP: £16.12

Range: N/ARank 157/280

–

CMP v/s 52-WL

£18.65£11.87

+35.8%CMP: £16.12

N/A

35.8%Rank 182/280

£18.65£11.87

+35.8%CMP: £16.12

Range: N/ARank 182/280

–

RSI 14D

050.2 - Bullish100

N/A

50.2Rank 50/280

050.2 - Bullish100

Range: N/ARank 50/280

–

MA50 - MA200

£14.95+1.13£16.08

N/A

BullishRank 39/280

£14.95+1.13£16.08

Range: N/ARank 39/280

–

MACD Rank

Golden Cross

MACD: 3.30

N/A

3.30Rank 100/280

Golden Cross

MACD: 3.30

Range: N/ARank 100/280

RSI (14 Day)

50.2

Bullish

0 (Oversold)50100 (Overbought)

Moving Averages

50 SMA£16.08

200 SMA£14.95

SignalGolden Cross (Bullish)

MACD3.30

Risk Metrics

Beta

N/A

3-Yr Std Dev

N/A

5-Yr Std Dev

N/A

Peer Comparison

How does HIK compare to other Healthcare stocks?

Overall Rank Comparison

Factor Score Comparison

Stock	Rank	Liquidity	Valuation	Profitability	Solvency	Mkt Trading	Technical
HIK	#73	52	127	186	144	180	107
AZN.L	#4	68	242	82	111	33	248
GNS.L	#63	33	133	153	79	96	277
CVSG.L	#90	60	211	200	191	200	78
CTEC.L	#115	36	182	206	147	236	211
ONT.L	#118	28	114	262	128	64	205
HLN.L	#126	71	222	169	150	240	232

Similar Stocks

Other top-ranked stocks in the Healthcare sector

Oxford Nanopore Technologies PLC

Catch Healthcare Events Before the Market Moves

SEC filings, FDA approvals, clinical trials, and regulatory events - scored for significance across 4 global markets.

Methodology Note

The analysis presented for Hikma Pharmaceuticals PLC is produced using Strategyland's proprietary 7-factor quantitative model, which evaluates each stock across Liquidity, Valuation, Profitability, Solvency, Asset Efficiency, Market Trading, and Technical dimensions. Individual factor scores and the composite rank reflect relative rankings within the FTSE 100 universe — a lower rank number indicates stronger performance in that category.

Underlying financial and market data is sourced from LSEG (London Stock Exchange Group) and processed through our scoring engine. Scores are recalculated as new data becomes available and should be interpreted as a systematic screening output, not a forecast of future share price performance.

This content is for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance and factor rankings are not indicative of future results. Please read our Risk Disclaimer before making any investment decisions.

Strategyland Research Center - strategyland.ukThis report is for informational purposes only. Not financial advice.